These methods offer to establish pathogenic enzyme levels resembling net enzyme activity reported in patients suffering from CDG, with phosphomannomutase 2-CDG (PMM2-CDG) as the most common form. This evidence concerns the gene PMM2 and congenital disorder of glycosylation.